MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$45,485K
EPS
-$0.75
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
42,123 32,483* 41,968 -
General and administrative expense
11,574 13,365* 13,627 -
Total operating expenses
53,697 45,848 55,595 -
Loss from operations
-53,697 -45,848* -55,595 -
Interest income
4,098 6,933* 5,093 -
Other expense, net
-62 -119* -108 -
Net loss before income taxes
--39,034* --
Effective tax rate
-0* --
Net loss
-49,661 -39,034* -50,610 -70,055
Unrealized gain (loss) on investments
---102
Comprehensive loss
----69,953
Comprehensive loss attributable to noncontrolling interests
---0
Net loss attributable to noncontrolling interests
-0* 0 -
Comprehensive loss attributable to cullinan
----69,953
Net loss attributable to cullinan
--39,034 -50,610 -
Net loss
-45,485 ---
Basic EPS
-0.75 -0.661 -0.77 -
Diluted EPS
-0.75 -0.661 -0.77 -
Basic Average Shares
60,462,000 59,025,000 59,075,000 -
Diluted Average Shares
60,462,000 59,025,000 59,075,000 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$45,485K something is missing$4,176K Net loss-$49,661K Interest income$4,098K Loss from operations-$53,697K Other expense, net-$62K Total operatingexpenses$53,697K Research and development$42,123K General andadministrative expense$11,574K

Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics, Inc. (CGEM)